BSE Sensex falls on weak Asia; Sun Pharma gains
MUMBAI (Reuters) – The BSE Sensex fell in early trade on Wednesday, tailing weak Asian peers and a Wall Street drop overnight, as investors await comments from the U.S. Federal Reserve on prospects for recovery in the world's largest economy.
At 9:59 a.m. (0429 GMT), the 30-share BSE index was down 1.2 percent at 14,894.30 points, with 28 stocks declining.
Sun Pharmaceutical, India's top drugmaker by market value, bucked the trend and rose 3 percent to 1241.95 rupees after it got the U.S. Food and Drug Administration's approval to launch its generic version of GlaxoSmithKline's Imitrex tablets to treat migraine.
The company also received U.S. regulatory approval to launch oxaliplatin injections, the copycat version of Sanofi-Aventis' Eloxatin that is used to treat colon and rectal cancer.
The 50-share NSE index was down 1 percent at 4,424.65.
(For more news on Reuters Money click in.reuters.com/money)
© Thomson Reuters 2009 All rights reserved
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India. Full Coverage
GLOBAL RECOVERY
Global economy in holding pattern - IMF
The global economy is in a holding pattern and vulnerable to more upheaval, the head of the IMF said, adding a lasting recovery will depend on policymakers taking the proper steps in the coming months. Full Article
India
US
UK
